GlassScriptPhysician profile
Jessica Tripp
NPI 1154052330
$1,188.12
in general payments reported to CMS, 2019-2025
22 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $76.23 · 2023: $383 · 2024: $431 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,111.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $136.91 | 2023-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Novo Nordisk INC | $128.03 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Boston Scientific Corporation | $122.30 | 2024 | Watchman Flx |
| Abbvie INC. | $118.90 | 2023-2024 | |
| Amgen INC. | $116.72 | 2023-2025 | Krystexxa, Repatha, Otezla |
| Axsome Therapeutics, INC. | $88.27 | 2024-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $81.71 | 2022-2023 | Farxiga, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.42 | 2022-2025 | Caplyta |
| Sage Therapeutics, LLC | $43.78 | 2025 | Zurzuvae |
| Otsuka America Pharmaceutical, INC. | $35.95 | 2022-2025 | Rexulti |
| Exact Sciences Corporation | $34.73 | 2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $33.95 | 2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.11 | 2022-2023 | Jardiance |
| Pfizer INC. | $27.13 | 2024 | |
| Daiichi Sankyo INC. | $25.98 | 2025 | Injectafer |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $18.90 | 2023 | Azstarys |
| Idorsia Pharmaceuticals US INC | $18.18 | 2023 | Quviviq |
| Lundbeck LLC | $17.42 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $14.47 | 2023 | Trintellix |
| Dexcom, INC. | $14.25 | 2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $14.01 | 2024 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $13.00 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Tripp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.